October 16, 2017
Shionogi and Purdue Pharma launched their peripherally-acting mu-opioid receptor antagonist Symproic (naldemedine) in the US on October 12. Symproic is indicated for opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. In Japan, the drug reached the market in...read more